These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28869796)

  • 1. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
    Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
    Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
    Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
    Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
    Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
    Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
    Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
    Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
    Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
    Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.
    Niwa Y; Adachi K; Tabata K; Ishida R; Hotta K; Ishida T; Mano Y; Ozawa Y; Minoshima Y; Funahashi Y; Semba T
    Mol Cancer Ther; 2023 Apr; 22(4):499-510. PubMed ID: 36696578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
    Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
    Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
    Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.